An interventional study of Level A and Level B in Acute Kidney Injury, sponsored by University of Pittsburgh. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Acute Kidney Injury by University of Pittsburgh — 2 open to participants now, 2 under way, none of them phase 3. Acute Kidney Injury · University of Pittsburgh.
Among the 10 studies in Acute Kidney Injury by University of Pittsburgh, this one is the only one that started in 2024, is one of 6 with no phase, and was the 9th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →2 of the 10 studies in Acute Kidney Injury by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18+
University of Pittsburgh · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2024.
This study's enrollment of 698 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 344 across the 6 interventional studies, 8,323 across the 4 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
1 of the studies in Acute Kidney Injury by University of Pittsburgh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06921603University of PittsburghPOCUS-Guided Diuresis for Decompensated Heart Failure | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Acute Kidney Injury by University of Pittsburgh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.
Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.
The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Physician-subject Inclusion
Physician-subject Exclusion
Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.
Patient-subject Inclusion
Patient-subject Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.
Other: Level A · Other: Level B
A Cerner EMR-based AKI passive alert which is standard of care at UPMC.
Other: Passive Alert
Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so \~ 3000 patients were included for the per protocol analysis to be impactful.
Time frame: up to 30 days
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.
Time frame: up to 30 days
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.
Time frame: up to 30 days
Nephrotoxic Burden
Drug.days\* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. \*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.
Time frame: up to 30 days
Prospective physician subjects within the study hospital service sites were emailed an opportunity to opt out in October/November 2023. All physicians within the hospital service clusters who did not opt out were enrolled under waiver of consent at the the start of the study intervention on February 15, 2024.
| Milestone | Protocolized Stage-based Intervention | Usual Care |
|---|---|---|
| Started | 306 | 392 |
| Cluster randomized to usual care, physician received intervention | 0 | 5 |
| Cluster randomized to intervention, physician received usual care | 4 | 0 |
| Completed | 251 | 229 |
| Not completed | 55 | 163 |
| Withdrew: Physician never cared for a patient meeting alert or patient criterion; no intervention delivered. | 55 | 163 |
Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so \~ 3000 patients were included for the per protocol analysis to be impactful.
| Patient encounters | Protocolized Stage-based Intervention | Usual Care |
|---|---|---|
| Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians | 1950 | 899 |
Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.
| Patient encounters | Protocolized Stage-based Intervention | Usual Care |
|---|---|---|
| No AKI to any Stage AKI | 159 | 95 |
| Stage 1 AKI to Stage 2+ | 249 | 112 |
| Stage 2 AKI to Stage 3 | 148 | 65 |
AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.
| days | Protocolized Stage-based Intervention | Usual Care |
|---|---|---|
| AKI at any stage | 4.88 (3.94 to 6.02) | 4.96 (4.01 to 6.13) |
| Stage 1 AKI | 1.43 (1.01 to 2.03) | 1.48 (1.04 to 2.11) |
| Stage 2 AKI | 0.92 (0.55 to 1.55) | 0.73 (0.43 to 1.24) |
| Stage 3 AKI | 0.37 (0.15 to 0.93) | 0.21 (0.08 to 0.53) |
Drug.days\* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. \*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.
| drug days | Protocolized Stage-based Intervention | Usual Care |
|---|---|---|
| Nephrotoxic Burden | 1.44 (1.15 to 1.80) | 1.37 (1.09 to 1.73) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Protocolized Stage-based Intervention | — | — | — |
| Usual Care | — | — | — |
There were 698 enrolled physicians but 480 physician participants because physicians were enrolled as members of randomized clusters, but some did not care for any patients who met the automated alert and patient inclusion criterion during the study period, therefore no intervention was delivered, no baseline characteristics are provided and no patient outcome data was included for those physicians.
| Age, Continuous(years) | Protocolized Stage-based Intervention | Usual Care | Total |
|---|---|---|---|
| Median | 43 (36 to 54) | 45 (39 to 55) | 44 (37 to 55) |
| Sex: Female, Male(Participants) | Protocolized Stage-based Intervention | Usual Care | Total |
|---|---|---|---|
| Female | 82 | 109 | 191 |
| Male | 167 | 119 | 286 |
| Race and Ethnicity Not Collected(Participants) | Protocolized Stage-based Intervention | Usual Care | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2024 to primary completion in Jul 2025, 17 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 17 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.